



Differences in e-Lung biomarker scores between treatment groups in post-hoc analysis of the ATLAS inhaled pirfenidone solution (AP01) for IPF clinical trial

Peter M George^{1,2}, Christian Rennison-Jones², Finja Ottink², Felix Woodhead³, Wassim Abou-Zeid², Olivier Joly², Deepthi Nair³, Aliki Sifostratoudaki², Ross Stewart², Claire Fernandez², Howard M. Lazarus³, Stephen Gerry⁴, George Harston^{2,5}, Anand Devaraj¹

1. Royal Brompton Hospital, London, UK 2. Brainomix, Oxford, UK 3. Avalyn Pharma Inc, Seattle, USA 4. Centre for Statistics in Medicine, University of Oxford, Oxford, UK 5. Oxford University Hospitals NHSFT, Oxford, UK

Rationale & Methods

- The weighted reticulovascular score (WRVS) is an automated CT biomarker of lung fibrosis
- WRVS quantifies a combination of reticulation and vascular structures (Figure 1)
- e-Lung imaging biomarkers were studied in a post-hoc analysis of a phase 1b clinical trial of inhaled pirfenidone (ATLAS study) in patients with idiopathic pulmonary fibrosis (IPF)

Patient Demographics

- 63 patients
- 100mg BD, n=28
- 50mg OD, n=35



Results

- e-Lung volume correlated strongly with FVC ($r=0.85$, $p<0.001$)
- In patients who received 50mg OD, baseline WRVS was associated with 5% FVC decline (OR 4.89 (1.14 to 26.7), $p=0.044$)
- Adjusting for baseline WRVS, 100mg BD dose associated with mean relative decrease in WRVS of -0.8% (-5.5% to +3.9%) vs. mean relative increase in WRVS of +5.3% (+1.2% to +9.5%) in the 50mg OD group ($p=0.06$) (Figure 2)
- This mirrored trends in mean relative FVC change of +0.6% (-2.7% to +3.9%) in the 100mg BD group vs -2.6% (-5.6% to +0.4%) in the 50mg OD group ($p=0.07$) (Figure 2)

Figure 1




Figure 1 Legend: Patient on 50mg once daily of nebulised pirfenidone. Stable FVC comparing baseline and 36 weeks. Rise in WRVS between baseline and follow-up CT and evidence of increased fibrosis on visual evaluation in line with progression of IPF

Figure 2




Figure 2 Legend: Relative change in WRVS and FVC between Baseline and 24-week timepoint

Conclusions

- e-Lung WRVS was associated with risk of future IPF progression in the low-dose pirfenidone group
- WRVS can identify treatment effects on CT, potentially even when the FVC is stable
- This research can assist in the optimisation of AI imaging tools to enrich clinical trials for progressive patients, to facilitate matching treatment arms and further explore novel trial end points

